Finding True North in Drug Development - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Finding True North in Drug Development

  • November 17, 2026

  • 9 min

Share

Clinical Scorecard: Finding True North in Drug Development

At a Glance

CategoryDetail
ConditionHematology and oncology drug development
Key MechanismsSirulnik describes translational research and clinical development as ways to bring drugs to patients, and emphasizes following the science and describing data precisely.
Target PopulationNot specified; the interview focuses on Sirulnik’s career in hematology and oncology drug development.
Care SettingIndustry drug development, including translational research and clinical trials

Key Highlights

  • Sirulnik says he moved from patient care and academia into industry to pursue broader impact through translational research and drug development.
  • He says César Milstein taught him to be precise when describing data and to minimize language that could be interpreted in multiple ways.
  • He says drug development should follow the science, ask relevant questions, and address problems relevant to patients, clinicians, and the organization.
  • He identifies regulatory bottlenecks, clinical-trial enrollment, and a changing competitive environment as external challenges that require agility and adjustment.
  • He advises aspiring drug developers to learn the work and organizational processes rather than skip steps.

Guideline-Based Recommendations

Diagnosis

    Management

    • Sirulnik says to follow the science, ask relevant questions, and address problems relevant to patients, clinicians, and the organization.
    • He says to keep patients and physicians as the focus while navigating external hurdles such as regulatory bottlenecks and clinical-trial enrollment.
    • He advises learning organizational processes, including discipline, structure, and standard operating procedures.

    Monitoring & Follow-up

    • Sirulnik says data drives the work in his organization.
    • He says to pay attention and adjust to changes in the external and competitive environment.

    Risks

    • Sirulnik identifies regulatory bottlenecks and clinical-trial enrollment as external hurdles.
    • He advises aspiring drug developers not to skip steps; the source does not specify consequences of doing so.

    Patient & Prescribing Data

    No specific prescribing population or treatment regimen is discussed; the interview concerns Sirulnik’s career and hematology and oncology drug development.

    Sirulnik says to follow the science, ask relevant questions, and address problems relevant to patients, clinicians, and the organization.

    Clinical Best Practices

    • Sirulnik says to follow the science and let data drive the work.
    • He says to minimize language that can be interpreted in multiple ways and to be precise in describing data.
    • He says development questions and problems should be relevant to patients, clinicians, and the organization.
    • He says to pay attention and adjust to external hurdles and changes in the competitive environment.
    • He advises aspiring drug developers to learn the work and organizational processes rather than skip steps.

    Related Resources & Content

      Original Source(s)

      Related Content